Molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) underlies the variable
outcomes achieved with immunochemotherapy. However, outcomes of gene expression …

Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …

Purpose Biologic heterogeneity is a feature of diffuse large B-cell lymphoma (DLBCL), and
the existence of a subgroup with poor prognosis and phenotypic proximity to Burkitt …

Purpose High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
(HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to …

Gene expression profiling (GEP) has stratified diffuse large B-cell lymphoma (DLBCL) into
molecular subgroups that correspond to different stages of lymphocyte development …

High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (HGBL-
DH/THs) include a group of diffuse large B-cell lymphomas (DLBCLs) with inferior outcomes …

The clinical significance of MYC and BCL2 genetic alterations in diffuse large B-cell
lymphoma (DLBCL), apart from translocations, has not been comprehensively investigated …

abstract Learning Objectives: After completing this course, the reader will be able to:
Describe the oncogenic drivers in DLBCL, especially those that have recently been …

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma worldwide and
consists of a heterogeneous group of cancers classified together on the basis of shared …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease whose prognosis is
associated with clinical features, cell-of-origin and genetic aberrations. Recent integrative …